Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRTX1719 in Advanced Solid Tumors With MTAP Deletion
NCT05245500Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MRTX1719 in solid tumor, mesothelioma, non-small cell lung cancer (NSCLC) and 2 more (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Dose-Limiting Toxicity at 21 days, Treatment-Related Adverse Event up to 2 years and 5 more. Started Jun 2022; status: recruiting.
02
Drugs
MRTX1719
03
Conditions
solid tumormesotheliomanon-small cell lung cancer (NSCLC)malignant peripheral nerve sheath tumor (MPNST)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05245500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05245500.